Head of Clinical Pharmacology & Pharmacometrics at Mission Therapeutics
Excited to present at ASN Kidney Week 2023 (2nd Nov) on our Mission Therapeutics abstract titled "MTX652, a Novel Selective USP30 Inhibitor for the Treatment of Acute Kidney Injury (AKI): Phase 1 Results in Healthy Subjects and Model-Driven Human Efficacious Dose Projections." I'd be very happy to catch up with colleagues there, so let me know if you are attending! #ASNKidneyWeek2023 #MTX652 #AKI #ClinicalTrial #MissionTherapeutics
Senior Medical Director at IQVIABiotech
1yAll the best to You, Pau! Congratulations!